e-learning
resources
Milan 2017
Sunday, 10.09.2017
Clinical problems in lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treatment of idiopathic pulmonary fibrosis (IPF) with nintedanib: an experience from the compassionate use program (CUP) in Estonia
A. Altraja (Tartu, Estonia)
Source:
International Congress 2017 – Clinical problems in lung diseases
Session:
Clinical problems in lung diseases
Session type:
Thematic Poster
Number:
726
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Altraja (Tartu, Estonia). Treatment of idiopathic pulmonary fibrosis (IPF) with nintedanib: an experience from the compassionate use program (CUP) in Estonia. 726
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Nintedanib for idiopathic pulmonary fibrosis (IPF): Data from the German compassionate use program (CUP)
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017
Late Breaking Abstract - Safety of combined pirfenidone (PFD) and nintedanib (NIN) in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – Late-breaking findings in pulmonary diseases
Year: 2017
The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP)
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Predicting life expectancy for pirfenidone and best supportive care (BSC) in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Development of a patient reported experience measure (PREM) for idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Treatment of idiopathic pulmonary fibrosis (IPF) with pentoxifylline (POF)
Source: Eur Respir J 2007; 30: Suppl. 51, 121s
Year: 2007
Epidemiology and mortality of non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung disease (PF-ILD) using the French national health insurance system (SNDS) database in France: the PROGRESS study
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients?
Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases
Year: 2017
IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015
Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF)
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020
Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012
Assessing the effectiveness of pirfenidone in changing the natural course of idiopathic pulmonary fibrosis: the data from European IPF Registry (eurIPFreg).
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept